The present review also found that the proportion of ER+ disease decreased with increasing tumor grade, reflecting perhaps the accelerated growth rate of ER− tumors, loss of estrogen expression in more advanced forms of the disease, and higher likelihood of false-negative results (due to difficulties in obtaining a biopsy of the original tumor). This evidence concerns the gene ESR1 and neoplasm.